Skip to main content

Together we are beating cancer

Donate now

Search Results: "PARP inhibitor"

Showing 12 out of 123 results
Cancer Research UK logo

The first ever Cancer Research UK prizes were presented this week at the National Cancer Research Institute Cancer Conference in Liverpool. The first ever Cancer Research UK prizes were presented this week at the National Cancer Research Institute Cancer Conference in Liverpool.

by Cancer Research UK | News | 10 November 2010

10 November 2010

Cancer Research UK logo

Scientists have developed a new test to select which patients with ovarian cancer will benefit from new drugs called PARP inhibitors, according to research presented at the NCRI Cancer Conference in Liverpool. Scientists have developed a new test to select which patients with ovarian cancer will benefit from new drugs called PARP inhibitors, according to research presented at the NCRI Cancer Conference in Liverpool.

by The National Cancer Research Institute (NCRI) | News | 8 November 2010

8 November 2010

Achilles statue
  • Science & Technology
  • Health & Medicine

Hitting cancer's Achilles' heel

New research from Professor Alan Ashworth, who has already been involved in the exploitation of one Achilles' heel, reveals another for us to target. New research from Professor Alan Ashworth, who has already been involved in the exploitation of one Achilles' heel, reveals another for us to target.

by Kat Arney | Analysis | 15 March 2010

15 March 2010

Cancer Research UK logo

Scientists have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today. Scientists have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today.

6 October 2009